Literature DB >> 16139782

Improving subjective scaling of pain using Rasch analysis.

Konrad Pesudovs1, Bruce A Noble.   

Abstract

UNLABELLED: Pain management outcomes assessment depends on valid measurement of pain. However, the validity of single-item scales, such as numeric or faces scales, with the assignment of ordinal numerical values to response scale categories, is questionable. The universal assumption that equal distances between response choices represent equal distances on the dimension being measured is essentially erroneous. Herein we demonstrate that Rasch analysis can be used to expose and repair scale inequity and reengineer scale structure. Thirty-one subjects with severe ocular surface disease repeatedly completed a 7-category faces pain scale. Rasch analysis demonstrated that response category 5 was underutilized, leading to disordering of the response scale. Collapsing category 5 into either category 4 or 6 produced an ordered 6-category faces scale that could be recalibrated with average Rasch person measures to create linear measurement on a continuous latent variable. The value of further alterations to the scale was explored, and the implication for scale redesign discussed. Rasch analysis could be applied to any subjective pain measure post-hoc to create linear measurement or applied during instrument development to optimize design. PERSPECTIVE: Single-item scales like the faces scale or a 1-10 numerical rating scale are commonly used for the subjective assessment of pain. However, scores applied to response categories are arbitrary, so do not represent equidistant steps in the underlying latent variable (pain). Scale inequities are easily demonstrable and repairable with Rasch analysis.

Entities:  

Mesh:

Year:  2005        PMID: 16139782     DOI: 10.1016/j.jpain.2005.04.001

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  9 in total

1.  Rasch analysis of the Ocular Surface Disease Index (OSDI).

Authors:  Bradley E Dougherty; Jason J Nichols; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

2.  Comparing quantification of pain severity by verbal rating and numeric rating scales.

Authors:  Marcel Dijkers
Journal:  J Spinal Cord Med       Date:  2010       Impact factor: 1.985

3.  Impact of Rating Scale Categories on Reliability and Fit Statistics of the Malay Spiritual Well-Being Scale using Rasch Analysis.

Authors:  Aqil Mohammad Daher; Syed Hassan Ahmad; Than Winn; Mohd Ikhsan Selamat
Journal:  Malays J Med Sci       Date:  2015 May-Jun

Review 4.  The challenges of assessing osteoarthritis and postoperative pain in dogs.

Authors:  Michele Sharkey
Journal:  AAPS J       Date:  2013-03-02       Impact factor: 4.009

5.  Taking into account the observers' uncertainty: a graduated approach to the credibility of the patient's pain evaluation.

Authors:  Patrice Rusconi; Paolo Riva; Paolo Cherubini; Lorenzo Montali
Journal:  J Behav Med       Date:  2009-11-07

6.  Mood Instability and Irritability as Core Symptoms of Major Depression: An Exploration Using Rasch Analysis.

Authors:  Lloyd Balbuena; Rudy Bowen; Marilyn Baetz; Steven Marwaha
Journal:  Front Psychiatry       Date:  2016-10-26       Impact factor: 4.157

7.  A Bounded Integer Model for Rating and Composite Scale Data.

Authors:  Gustaf J Wellhagen; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

8.  Measuring Anxiety in Patients With Early-Stage Parkinson's Disease: Rasch Analysis of the State-Trait Anxiety Inventory.

Authors:  Hui-Jun Yang; Joon-Ho Ahn; Jungsun Lee; Won Kee Lee; Jiho Lee; Yangho Kim
Journal:  Front Neurol       Date:  2019-02-13       Impact factor: 4.003

9.  Development of the Vision Impairment in Low Luminance Questionnaire.

Authors:  Susanne G Pondorfer; Jan H Terheyden; Helen Overhoff; Jana Stasch-Bouws; Frank G Holz; Robert P Finger
Journal:  Transl Vis Sci Technol       Date:  2021-01-06       Impact factor: 3.283

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.